Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

Core Viewpoint - Pulmatrix, Inc. has announced a series of transactions with MannKind Corporation, including a cross-licensing agreement and the transfer of its Bedford, Massachusetts R&D facility, which will enhance the development of innovative inhaled therapies using Pulmatrix's iSPERSE™ technology [2][3][4]. Group 1: Transaction Details - The cross-licensing agreement allows Pulmatrix to use MannKind's Cricket® inhalation device for the inhaled delivery of its proprietary formulation PUR3100, a dihydroergotamine (DHE) product, and other dry powder formulations for neurological diseases [3][4]. - MannKind will assume the lease of Pulmatrix's R&D facility, including all leasehold improvements and laboratory equipment, which will extend Pulmatrix's cash runway into 2026 [3][4]. - The agreements are expected to close in July 2024 [4]. Group 2: Technology and Product Pipeline - Pulmatrix's iSPERSE™ technology enables the development of inhaled therapies that address serious central nervous system and pulmonary diseases, aiming to improve therapeutic delivery and patient outcomes [5][8]. - The company's product pipeline includes treatments for acute migraine, chronic obstructive pulmonary disease (COPD), and allergic bronchopulmonary aspergillosis (ABPA) [5]. - PUR3100, an orally inhaled formulation of DHE, is designed for the treatment of acute migraine, targeting a significant patient population in the U.S. [7].